Teva fails to reclassify MS drug to thwart generics
Teva Charged With Paying Kickbacks to Increase Sales of MS Drug - Health Law Offices of Anthony C. Vitale
Novartis' Gilenya tops Teva giant Copaxone in head-to-head MS study | Fierce Pharma
Opioid maker Teva agrees to $4.25B settlement with Iowa, other states
Teva Class Action Claims Company Suppressed Competition For Generic Version Of MS Drug Copaxone - Top Class Actions
Teva sues FDA over bid to block approval of generic Copaxone | Mint
EU says Teva blocked generics to MS drug Copaxone | pharmaphorum
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed - Ypsomed - Canada
Antitrust Action Targets Teva Multiple Sclerosis Drug | New Jersey Law Journal
3rd Oral Drug to Treat MS Is Approved by the F.D.A. - The New York Times
Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and Development
Here's the Simple Reason Why Multiple Sclerosis Drugs Cost So Much | The Motley Fool
Health: The Price of Multiple Sclerosis Drugs Only Goes Up - Bloomberg
Teva knocked as competition fears grow for MS drug | Financial Times
BCBS Vermont suing Teva Pharmaceuticals over MS drug marketing | Healthcare Finance News
Drug Manufacturer Teva to Pay $523M to New York in Opioid Settlement
Teva 'Plagued By Problems,' Downgraded On Lost MS Drug Patents, DOJ Probe | Stock News & Stock Market Analysis - IBD
Mylan Cuts Price of Generic Copaxone Offering by 60% | Ctech
Multiple sclerosis and drug discovery: A work of translation - eBioMedicine
Patients struggle to afford medication for MS
